 viral loads in chronic infection: retrospective analysis of cohorts from the UK and South Africa Louise O Downs^{1,2}, Sabeehah Vawda³, Phillip Armand Bester³, 	2,6,9
 analysis of cohorts from the UK and South Africa Louise O Downs^{1,2}, Sabeehah Vawda³, Phillip Armand Bester³, 	2,6,9
4 5 Louise O Downs ^{1,2} , Sabeehah Vawda ³ , Phillip Armand Bester ³ ,	2,6,9 ,
5 Louise O Downs ^{1,2} , Sabeehah Vawda ³ , Phillip Armand Bester ³ ,	2,6,9 ,
	2,6,9
6 Katrina A Lythgoe ^{4,5} , Tingyan Wang ² , Anna L McNaughton ² , David A Smith	,
7 Tongai Maponga ⁷ , Oliver Freeman ^{6,11} , Kinga A Várnai ^{6,9} , Jim Davies ^{6,10}	
8 Kerrie Woods ^{6,9} , Christophe Fraser ⁴ , Eleanor Barnes ^{2,6,8} ,	
9 Dominique Goedhals ³ , Philippa C Matthews ^{1,2,6}	
10	
¹¹ ¹ Department of Infectious Diseases and Microbiology, Oxford University Hosp	itals
12 NHS Foundation Trust, Oxford, UK;	
¹³ ² Nuffield Department of Medicine, Medawar Building for Pathogen Research,	
14 University of Oxford, Oxford, UK;	
³ Division of Virology, University of the Free State and National Health Laborat	ory
16 Service, Bloemfontein, South Africa;	
⁴ Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, I	Nuffield
18 Department of Medicine, University of Oxford, United Kingdom	
⁵ Department of Zoology, University of Oxford, M Medawar Building for Pathog	jen
20 Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK	
⁶ National Institute of Health Research Health Informatics Collaborative, NIHR	Oxford
22 Biomedical Research Centre, Oxford, UK;	
⁷ Department of Virology, University of Stellenbosch, Tygerberg Hospital, Cap	е
24 Town, South Africa	
²⁵ ⁸ Department of Hepatology, Oxford University Hospitals NHS Foundation Tru	st,
26 Oxford, UK;	
⁹ Oxford University Hospitals NHS Foundation Trust, Oxford, UK;	
¹⁰ Department of Computer Science, University of Oxford, Oxford, UK;	
²⁹ ¹¹ Nuffield Department of Population Health, University of Oxford, Oxford, UK.	
30	
32 CONFLICT OF INTEREST: NII	
 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to quide clinic: 	al practice.

35 CORRESPONDING AUTHOR

Professor Philippa C Matthews: 36 Email: philippa.matthews@ndm.ox.ac.uk 37 38 Address: Medawar Building for Pathogen Research, South Parks Road, 39 Oxford OX1 3SY, UK Telephone: 0044 1865 271973 40 41 **AUTHORS' CONTRIBUTIONS** 42 43 • Study concept and design: PCM, ALM. Development of the health informatics (HIC) pipeline: DS, JD, OF, KV, KW 44 • Acquisition and interpretation of South African data: SV, PAB, TM, DG, LOD 45 • Acquisition and interpretation of UK data: LOD, DAS, ALM 46 ٠ Analysis of the data: TW, CF, KAL 47 • Literature review: LOD, PCM 48 • Wrote the manuscript: LOD, PCM 49 ٠ 50 Critical revision of manuscript: LOD, PCM, ALM, KAL, CF • 51 Edited and approved the final manuscript: All authors • 52 53 **FUNDING** 54 PCM is funded by the Wellcome Trust (ref 110110). KAL is funded by the Wellcome 55 56 Trust and the The Royal Society (ref 107652/Z/15/Z). LOD is funded by the NIHR. 57

58 Introduction

Hepatitis B virus (HBV) DNA viral loads (VL) show wide variation between individuals with chronic hepatitis B (CHB) infection, and are used to determine treatment eligibility (1). There are few refined descriptions of VL distribution in CHB, and limited understanding of the biology that underpins these patterns. We set out to describe the VL distribution in independent cohorts from the UK and South Africa, to identify associated host characteristics, and to compare with VL in HIV-1 and hepatitis C (HCV) infection.

66

67 Methods

We retrospectively collected baseline and longitudinal HBV VL measurements, 68 69 HBeAg status and demographic data from treatment-naïve adults with CHB between 70 2011-2016 from electronic records at a UK teaching hospital (n=351), as described 71 previously (2). We also analysed all HBV VL data from the South African National Health Laboratory Service (NHLS), representing a four-year period from 1st January 72 73 2015 (n=6506). We used longitudinal data from the UK HBeAg-negative cohort, and 74 from South African patients with detectable viraemia to investigate the relative 75 contributions of within- and between-host variation to VL variability. A large 76 contribution of between-host variation would provide support for a set-point viral load 77 (SPVL), as is observed for HIV. We compared HBV VLs with pre-treatment HCV VLs 78 from the same UK cohort (n=925) and HIV SPVLs from a previous European study 79 (n=1581) (3). More details of clinical cohorts and statistical analysis are presented in 80 Suppl. methods.

81

82 **Results**

In the UK cohort, overall median HBV VL was $3.4 \log_{10} IU/mL$; $95\% CI 3.2 - 3.5 \log_{10}$ IU/mL (equivalent to median $4.2 \log_{10}$ copies/ml). There was a bimodal VL distribution (Fig 1A) with peaks as follows:

- HBeAg-negative infection (accounting for 304/351 (87%) of measurements):
 median VL 3·2 log₁₀ IU/mL (95% CI 3·0 3·4); right-skewed distribution (Fig
 1A).
- HBeAg-positive infection (accounting for 47/351 (13%) of measurements):
 median VL 7.6 log₁₀ IU/mL (95% CI 5.6 8.2); left-skewed distribution (Fig
 1B)

In the South African dataset (HBeAg status not determined), median HBV VL was $4.6 \log_{10} IU/mL$ (95% CI 3.9 - 4.0), with a bimodal distribution and right-skew (Fig 1C).

95

For the UK data we investigated whether sex, age or ethnicity had any influence on
VL; the only significant association was lower VL with increasing age in the HBeAgpositive group (p=0.01 by Kruskal Wallis, Suppl. Fig 1).

99

Longitudinal data were available for 299 patients in the UK cohort and 874 patients in the South African cohort. Inter-patient variation accounted for 82.7% and 88.0% of the variability in UK and South African datasets respectively, whilst within-patient variation accounted for 17.3% and 12.0%. This provides support for a stable SPVL within individuals with CHB.

105

Median HIV VL was $4.5 \log_{10}$ copies/mL and median HCV VL was $6.0 \log_{10}$ IU/ml ($6.4 \log_{10}$ copies/ml), with a left skew and no bimodal distribution (Fig 1D,E), and significantly different viraemia compared to HBV (p<0.0001; Fig 1F).

109

110 **Discussion**

HBV VL distribution in our diverse UK population is in keeping with a large South African dataset, as well as other previously published studies (e.g. (4–6)). Although the bimodal distribution of HBV VL is consistent between cohorts, descriptions of this pattern have not previously been carefully refined. The relationship between HBeAg status and VL is in keeping with the role of HBeAg in immunomodulation (7).

116

117 HBV viral loads in HBeAg-negative infection are significantly lower than HCV and HIV, which may relate to differences in viral population structure, viral fitness, 118 119 influence of host immune responses, and the availability of target cells. These 120 factors might also explain why HIV, HCV and HBeAg-positive infection have left skew VL distributions, whereas HBeAg-negative infection has a right skew. This is 121 122 the first study to explore the concept of SPVL in HBV infection, with between-host 123 factors explaining over 80% of the variation in VL measurements during HBeAg-124 negative CHB.

126 Our data represent a small but well-defined UK cohort, and a much larger South 127 African population without the benefit of relevant supporting metadata; long-term 128 aspirations will be to investigate larger VL datasets together with robust clinical and 129 laboratory parameters.

130

131 Next generation sequencing (NGS) has the potential to increase our understanding 132 of HBV but approximately 50% of cases fall below the current sequencing threshold 133 of ~3 log₁₀ IU/mL (8). Enhanced descriptions of HBV VL may shed light on the 134 biology of chronic HBV infection, improve understanding of risk factors for 135 transmission and disease progression at a population level, inform optimisation of 136 viral sequencing methods, and help to stratify patients for clinical trials and 137 treatment.

138

139 Metadata

140 The metadata underpinning this analysis are available on-line:

141 https://figshare.com/s/cd8b046346250dd349b0

142 On acceptance of this manuscript for publication, the data will be made available

143 through a permanent DOI: 10.6084/m9.figshare.11365082

144

145

Figure 1: Distribution of viral loads for adults with chronic infection with HBV, 147

148 **HIV and HCV**



References 152 153 154 1. Lampertico P, Agarwal K, Berg T et al. EASL 2017 Clinical Practice Guidelines on the 155 management of hepatitis B virus infection. J Hepatol. 2017;67(2):370-98. 156 2. Downs LO, Smith DA, Lumley SF et al. Electronic Health Informatics Data To Describe 157 Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in 158 Chronic Hepatitis B Virus Infection. MBio. 2019. 25;10(3). 159 3. Blanquart F, Wymant C, Cornelissen M et al. Viral genetic variation accounts for a third of 160 variability in HIV-1 set-point viral load in Europe. PLoS Biol. 2017. 15(6):e2001855. 161 4. Pyne MT, Vest L, Clement J et al. Comparison of three roche hepatitis B virus viral load assay 162 formats. J Clin Microbiol. 2012; 50(7):2337-42. 163 5. Meldal BHM, Bon AH, Prati D, Ayob Y, Allain JP. Diversity of hepatitis B virus infecting 164 Malaysian candidate blood donors is driven by viral and host factors. J Viral Hepat. 2011; 165 18(2):91-101. 166 6. Allain JP, Candotti D, Soldan K et al. The risk of hepatitis B virus infection by transfusion in 167 Kumasi, Ghana. Blood. 2003. 101(6):2419-25. 168 Milich D, Liang TJ. Exploring the Biological Basis of Hepatitis B e Antigen in Hepatitis B Virus 7. 169 Infection. Hepatology. 2003. 38:1075-86. 170 8. McNaughton AL, D'Arienzo V, Ansari MA et al. Insights From Deep Sequencing of the HBV 171 Genome—Unique, Tiny, and Misunderstood. Gastroenterology. 2019;156(2):384-99. 172